Screener
4D Molecular Therapeutics FDMT Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | 64,980 | 40,699 |
| General and administrative | 11,687 | 12,936 |
| Total operating expenses | 76,667 | 53,635 |
| Loss from operations | (73,620) | (53,621) |
| Other income (expense): | ||
| Interest income | 4,864 | 5,582 |
| Other income (expense), net | (4) | 67 |
| Total other income, net | 4,860 | 5,649 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's operating income?
- 4D Molecular Therapeutics (FDMT) reported operating income of -$73.62M in Q1 2026.
- How has 4D Molecular Therapeutics's operating income changed year-over-year?
- 4D Molecular Therapeutics's operating income decreased by 37.3% year-over-year, from -$53.62M to -$73.62M.
- What is the long-term trend for 4D Molecular Therapeutics's operating income?
- Over 4 years (2021 to 2025), 4D Molecular Therapeutics's operating income has grown at a 25.0% compound annual growth rate (CAGR), from -$71.33M to -$174.26M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about 4D Molecular Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude